Medical specialists from Canada tagged as investigators in clinical trials studying Hodgkin Disease

Total 13 results

Angela S. Punnett
Seen in:
- Ontario, Toronto, Hospital for Sick Children
Trials:
- NCT05675410 (Principal Investigator)
Conditions:
- Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Ashley Chopek
Seen in:
- Manitoba, Winnipeg, CancerCare Manitoba
Trials:
- NCT04759586 (Principal Investigator)
- NCT05457556 (Principal Investigator)
- NCT03794349 (Principal Investigator)
- NCT03067181 (Principal Investigator)
- NCT05099003 (Principal Investigator)
- NCT03914625 (Principal Investigator)
- NCT03007147 (Principal Investigator)
- NCT02402244 (Principal Investigator)
- NCT05304585 (Principal Investigator)
- NCT04684368 (Principal Investigator)
- NCT04322318 (Principal Investigator)
- NCT03817398 (Principal Investigator)
- NCT04726241 (Principal Investigator)
- NCT05675410 (Principal Investigator)
- NCT04994132 (Principal Investigator)
- NCT03959085 (Principal Investigator)
- NCT03223753 (Principal Investigator)
Conditions:
Bruno Michon
Seen in:
- Quebec, CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
- Quebec, Centre Hospitalier Universitaire de Quebec
Trials:
- NCT04759586 (Principal Investigator)
- NCT04576117 (Principal Investigator)
- NCT04166409 (Principal Investigator)
- NCT01790152 (Principal Investigator)
- NCT03794349 (Principal Investigator)
- NCT03533582 (Principal Investigator)
- NCT03067181 (Principal Investigator)
- NCT05099003 (Principal Investigator)
- NCT03914625 (Principal Investigator)
- NCT03007147 (Principal Investigator)
- NCT02402244 (Principal Investigator)
- NCT05304585 (Principal Investigator)
- NCT04684368 (Principal Investigator)
- NCT04322318 (Principal Investigator)
- NCT03817398 (Principal Investigator)
- NCT04726241 (Principal Investigator)
- NCT04293562 (Principal Investigator)
- NCT05675410 (Principal Investigator)
- NCT02176967 (Principal Investigator)
- NCT00904241 (Principal Investigator)
- NCT04994132 (Principal Investigator)
- NCT03959085 (Principal Investigator)
Conditions:
Craig Erker
Seen in:
- Nova Scotia, Halifax, IWK Health Centre
Trials:
- NCT04759586 (Principal Investigator)
- NCT04576117 (Principal Investigator)
- NCT02724579 (Principal Investigator)
- NCT03871257 (Principal Investigator)
- NCT04166409 (Principal Investigator)
- NCT03794349 (Principal Investigator)
- NCT03533582 (Principal Investigator)
- NCT03067181 (Principal Investigator)
- NCT05099003 (Principal Investigator)
- NCT03914625 (Principal Investigator)
- NCT03007147 (Principal Investigator)
- NCT02402244 (Principal Investigator)
- NCT03126916 (Principal Investigator)
- NCT05304585 (Principal Investigator)
- NCT05235165 (Principal Investigator)
- NCT04322318 (Principal Investigator)
- NCT03817398 (Principal Investigator)
- NCT04726241 (Principal Investigator)
- NCT04293562 (Principal Investigator)
- NCT00898365 (Principal Investigator)
- NCT05675410 (Principal Investigator)
- NCT02176967 (Principal Investigator)
- NCT05602194 (Principal Investigator)
- NCT04994132 (Principal Investigator)
- NCT03959085 (Principal Investigator)
- NCT04089358 (Principal Investigator)
Conditions:
John Kuruvilla, M.D.
Seen in:
- Ontario, Toronto, Princess Margaret Cancer Centre
Trials:
- NCT04510636 (Principal Investigator)
Conditions:
Josee Brossard
Seen in:
- Quebec, Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
Trials:
- NCT04576117 (Principal Investigator)
- NCT03871257 (Principal Investigator)
- NCT04166409 (Principal Investigator)
- NCT03794349 (Principal Investigator)
- NCT03067181 (Principal Investigator)
- NCT03914625 (Principal Investigator)
- NCT03007147 (Principal Investigator)
- NCT02402244 (Principal Investigator)
- NCT05304585 (Principal Investigator)
- NCT05235165 (Principal Investigator)
- NCT04322318 (Principal Investigator)
- NCT04293562 (Principal Investigator)
- NCT05675410 (Principal Investigator)
- NCT02176967 (Principal Investigator)
- NCT04994132 (Principal Investigator)
- NCT03959085 (Principal Investigator)
Conditions:
Kelly Davison
Seen in:
- Quebec, Montreal, Royal Victoria Hospital, McGill University Health Centre
Trials:
- NCT01716806 (Principal Investigator)
Conditions:
- Hodgkin Disease;
- Peripheral T Cell Lymphoma
Monia Marzouki
Seen in:
- Quebec, Montreal, Centre Hospitalier Universitaire Sainte-Justine
Trials:
- NCT04759586 (Principal Investigator)
- NCT04576117 (Principal Investigator)
- NCT03155620 (Principal Investigator)
- NCT02724579 (Principal Investigator)
- NCT05071209 (Principal Investigator)
- NCT03871257 (Principal Investigator)
- NCT05286801 (Principal Investigator)
- NCT03794349 (Principal Investigator)
- NCT03533582 (Principal Investigator)
- NCT03067181 (Principal Investigator)
- NCT05099003 (Principal Investigator)
- NCT03007147 (Principal Investigator)
- NCT02402244 (Principal Investigator)
- NCT05359237 (Principal Investigator)
- NCT05304585 (Principal Investigator)
- NCT04684368 (Principal Investigator)
- NCT05235165 (Principal Investigator)
- NCT04322318 (Principal Investigator)
- NCT03817398 (Principal Investigator)
- NCT04726241 (Principal Investigator)
- NCT04293562 (Principal Investigator)
- NCT05675410 (Principal Investigator)
- NCT04994132 (Principal Investigator)
Conditions:
Nathalie Johnson
Seen in:
- Quebec, Montreal, Jewish General Hospital
Trials:
- NCT01716806 (Principal Investigator)
Conditions:
- Hodgkin Disease;
- Peripheral T Cell Lymphoma
Sarah J. McKillop
Seen in:
- Alberta, Edmonton, University of Alberta Hospital
Trials:
- NCT04759586 (Principal Investigator)
- NCT04576117 (Principal Investigator)
- NCT03533582 (Principal Investigator)
- NCT03067181 (Principal Investigator)
- NCT03914625 (Principal Investigator)
- NCT03007147 (Principal Investigator)
- NCT02402244 (Principal Investigator)
- NCT05304585 (Principal Investigator)
- NCT04684368 (Principal Investigator)
- NCT05235165 (Principal Investigator)
- NCT04322318 (Principal Investigator)
- NCT03817398 (Principal Investigator)
- NCT04726241 (Principal Investigator)
- NCT04293562 (Principal Investigator)
- NCT00898365 (Principal Investigator)
- NCT05675410 (Principal Investigator)
- NCT02176967 (Principal Investigator)
- NCT00904241 (Principal Investigator)
- NCT04994132 (Principal Investigator)
- NCT03959085 (Principal Investigator)
- NCT04089358 (Principal Investigator)
- NCT00082745 (Principal Investigator)
Conditions:
Selay Lam
Seen in:
- Ontario, London, London Health Sciences Centre - Victoria Hospital
Trials:
- NCT01716806 (Principal Investigator)
Conditions:
- Hodgkin Disease;
- Peripheral T Cell Lymphoma
Stephanie Mourad
Seen in:
- Quebec, Montreal, The Montreal Children's Hospital of the MUHC
Trials:
- NCT04759586 (Principal Investigator)
- NCT03871257 (Principal Investigator)
- NCT04166409 (Principal Investigator)
- NCT03067181 (Principal Investigator)
- NCT03914625 (Principal Investigator)
- NCT03007147 (Principal Investigator)
- NCT04684368 (Principal Investigator)
- NCT05235165 (Principal Investigator)
- NCT04322318 (Principal Investigator)
- NCT03817398 (Principal Investigator)
- NCT04726241 (Principal Investigator)
- NCT05675410 (Principal Investigator)
- NCT04994132 (Principal Investigator)
Conditions:
Sylvie Lachance
Seen in:
- Quebec, Montreal, CIUSSS de L'Est de l'lle de Montreal / installation Hopital Maisonneuve-Rosemont
Trials:
- NCT01716806 (Principal Investigator)
Conditions:
- Hodgkin Disease;
- Peripheral T Cell Lymphoma

Clinical Trials on Hodgkin Disease

Tessa Therapeutics

Active, not recruiting

Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)

Hodgkin Lymphoma, Adult | Hodgkin Disease Recurrent | Hodgkin Disease Refractory | Hodgkin Disease, Pediatric

United States
Tessa Therapeutics
Bristol-Myers Squibb

Active, not recruiting

Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy (ACTION)

Classical Hodgkin Lymphoma | Hodgkin Disease Recurrent | Hodgkin Disease Refractory

United States
Shandong Provincial Hospital

Unknown

Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma

Lymphoma, Non-Hodgkin;Hodgkin Disease

China
University of Washington

Recruiting

Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma

United States
Akeso
Peking University Cancer Hospital & Institute

Recruiting

A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma

Hodgkin Disease Lymphoma

China
Stanford University

Completed

Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma

Lymphoma | Hodgkin Disease | Lymphoma, Hodgkin Disease | Lymphoma: Hodgkin

United States
Grupo Argentino de Tratamiento de la Leucemia Aguda
Takeda

Recruiting

RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT

Refractory Hodgkin Lymphoma | Hodgkin Lymphoma, Adult | Relapsed Hodgkin's Disease, Adult

Argentina
Seagen Inc.
Millennium Pharmaceuticals, Inc.

Completed

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Disease, Hodgkin

United States, United Kingdom, France, Romania, Poland, Italy, Bulgaria, Hungary, Russian Federation, Czechia, Spain, Germany, Serbia
Seagen Inc.
Millennium Pharmaceuticals, Inc.

Completed

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

Disease, Hodgkin

United States, France, Canada, Belgium, Italy
Seagen Inc.
Millennium Pharmaceuticals, Inc.

Completed

A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

Disease, Hodgkin

United States, Canada

Medical specialists from Canada tagged as investigators in clinical trials studying Hodgkin Disease

Clinical Trials on Hodgkin Disease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations